Caribou Biosciences Plans To End Both CAR-T Programs, Cut Staff And Explore A Sale Or Merger
An 8-K puts restructuring costs at $15 million to $19 million, with Wedbush engaged as exclusive financial advisor.
Caribou Biosciences' board approved a plan to discontinue its two allogeneic CAR-T programs, vispa-cel and CB-011, and to explore strategic alternatives, according to an 8-K filed Tuesday. The company expects restructuring expenses of about $15 million to $19 million, much of it in the fourth quarter of 2026.
What the 8-K says
The board approved the restructuring on October 2, a Friday, and the company disclosed it Tuesday. Nasdaq halted trading at 16:01:00 ET on Tuesday under code T1, news pending, with no resumption time posted. The filing was accepted at 4:07 p.m. ET.
The plan covers a planned end to clinical trials and further development of vispa-cel, aimed at relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, aimed at relapsed or refractory multiple myeloma. It also includes a substantial workforce reduction and other cost cuts.
The board pointed to the financing environment for allogeneic CAR-T therapies, which it said has made it increasingly challenging to raise the capital needed to advance the programs. CEO Rachel Haurwitz, in the press release, called it "an extraordinarily difficult decision" and said vispa-cel is pivotal trial-ready, with FDA alignment already reached on the phase 3 trial design.
The cost and the workforce
Severance, continued healthcare coverage and related costs account for roughly $10 million to $11 million. Winding down the ANTLER and CaMMouflage phase 1 trials adds $5 million to $8 million.
The cuts come in phases. Most affected employees are expected to leave in the fourth quarter of 2026, while a limited number stay through the strategic review to support a transaction and the wind-down.
Caribou also intends to terminate contracts, resolve intellectual property licensing arrangements, and sublease or end its facility leases. It cannot yet estimate charges for the lease, contract terminations or asset impairments, and will amend the 8-K within four business days of making a determination. A long-term follow-up study for patients previously treated with its investigational products is ongoing.
The strategic review
The board formed a Transaction Committee to evaluate options, which include a merger, acquisition, business combination or other deal involving the company or its assets. Wedbush Securities is the exclusive financial advisor.
Caribou has set no timeline and does not plan further updates until the board approves a course of action, the review ends, or disclosure is otherwise required. It gave no commitment that the review will produce a transaction.
Chief Financial Officer Sriram Ryali's employment will end when Caribou signs a binding agreement for a strategic alternative. The filing says that would count as a termination without cause, entitling him to severance under his employment agreement.
The company held $113.8 million in cash, cash equivalents and marketable securities as of June 30, 2026, according to the press release.
The next dated item is the promised 8-K amendment, due within four business days after Caribou can estimate its lease, contract and impairment charges.
